Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_assertion type Assertion NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_head.
- NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_assertion description "[While somatostatin receptors (sst), through somatostatin-radiolabeled analogs, are used, mainly in second line, in the diagnosis and treatment of pheochromocytomas (PCC) and paragangliomas (PGL), the clinical significance of dopamine receptor subtype 2 (D?) in PCC/PGL is unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.
- NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_assertion evidence source_evidence_literature NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.
- NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_assertion SIO_000772 21335363 NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.
- NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_assertion wasDerivedFrom befree-2016 NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.
- NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_assertion wasGeneratedBy ECO_0000203 NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.